| Dr Cynthia Louise Morgan, MD, MPH, FACPM | |
|
164 Nc 9203, Pettigrew, AR 72752-9501 | |
| (870) 861-5113 | |
| Not Available |
| Full Name | Dr Cynthia Louise Morgan |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine |
| Experience | 42 Years |
| Location | 164 Nc 9203, Pettigrew, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891323184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | E-13034 (Arkansas) | Primary |
| Entity Name | Ozark Center For Lifestyle Medicine, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831791094 PECOS PAC ID: 6901214543 Enrollment ID: O20210420000583 |
News Archive
InfoLogix, Inc., a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, announced today it has successfully launched a customized HealthTrax mobility solution for University Health System's 604-bed acute care hospital and 20 ambulatory clinics in San Antonio, Texas.
Hospira, Inc has announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage System.
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.
Researchers at the University of Arkansas and their collaborators will use a $1.4 million grant from the U.S. Department of Defense to study the origin of Leigh's disease, a rare and incurable disease that affects the central nervous system.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cynthia Louise Morgan, MD, MPH, FACPM Hc 33 Box 53a, Pettigrew, AR 72752-9501 Ph: (870) 861-5113 | Dr Cynthia Louise Morgan, MD, MPH, FACPM 164 Nc 9203, Pettigrew, AR 72752-9501 Ph: (870) 861-5113 |
News Archive
InfoLogix, Inc., a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, announced today it has successfully launched a customized HealthTrax mobility solution for University Health System's 604-bed acute care hospital and 20 ambulatory clinics in San Antonio, Texas.
Hospira, Inc has announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage System.
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.
Researchers at the University of Arkansas and their collaborators will use a $1.4 million grant from the U.S. Department of Defense to study the origin of Leigh's disease, a rare and incurable disease that affects the central nervous system.
› Verified 6 days ago